Top Page
Nuformix Plc
(LSE:NFX)
Nuformix Plc (NFX) vs. iShares MSCI United Kingdom ETF (EWC)
Nuformix Plc Business Overview & Revenue Model
Nuformix Plc Financial Statement Overview
| Breakdown | Sep 2024 | Sep 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 50.00K | 195.55K | 535.00K |
| Gross Profit | 0.00 | -36.75K | 11.33K | 86.72K | 201.41K |
| EBITDA | -477.19K | -581.90K | -1.23M | -1.28M | -832.90K |
| Net Income | -3.64M | -572.98K | -1.11M | -1.25M | -756.38K |
Balance Sheet | |||||
| Total Assets | 970.54K | 4.42M | 4.98M | 6.01M | 5.13M |
| Cash, Cash Equivalents and Short-Term Investments | 20.21K | 202.55K | 464.10K | 1.67M | 543.77K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 75.39K |
| Total Liabilities | 254.97K | 222.99K | 237.86K | 324.62K | 383.91K |
| Stockholders Equity | 715.57K | 4.20M | 4.74M | 5.69M | 4.74M |
Cash Flow | |||||
| Free Cash Flow | -331.88K | -397.49K | -1.35M | -848.83K | -770.80K |
| Operating Cash Flow | -331.88K | -397.49K | -1.35M | -848.22K | -727.60K |
| Investing Cash Flow | 0.00 | 33.33K | 0.00 | 43.72K | -43.20K |
| Financing Cash Flow | 149.54K | 189.79K | 139.98K | 1.93M | 1.31M |
Nuformix Plc Technical Analysis
Nuformix Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥345.34B | 10.96 | -2.99% | 2.56% | 11.77% | -10.16% | |
53 Neutral | £3.58M | 0.58 | 56.96% | ― | -55.66% | ― | |
53 Neutral | £2.43M | ― | -50.84% | ― | 418.49% | 27.86% | |
47 Neutral | £24.37M | ― | -87.30% | ― | ― | 71.17% | |
46 Neutral | £106.27M | ― | 167.16% | ― | -100.00% | -23.91% | |
42 Neutral | £1.80M | ― | -153.80% | ― | ― | -462.50% |
Nuformix Plc Corporate Events
Nuformix plc has announced its unaudited results for the six months ending March 31, 2025, highlighting significant progress with its lead asset, NXP002, a potential inhaled treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products regarding Orphan Drug Designation for NXP002, validating its potential efficacy in treating fibrotic lung diseases. Financially, the company reported a loss on ordinary activities of £376,668 and raised additional funds through share subscriptions. The announcement underscores Nuformix’s focus on securing partnerships and licensing agreements to advance NXP002’s development and commercialization.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Neutral.
Nuformix Plc’s overall stock score reflects severe financial challenges, including a lack of revenue and persistent losses. While recent positive corporate developments and technical momentum offer some optimism, they are overshadowed by significant financial instability and negative valuation metrics.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix plc announced that its lead program, NXP002, has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products for Orphan Drug Designation in treating Idiopathic Pulmonary Fibrosis (IPF). This designation highlights NXP002’s potential benefit for IPF patients, offering a clinically relevant advantage, especially for those intolerant to existing anti-fibrotic agents. The company anticipates the European Commission’s final ratification and plans to apply for US FDA orphan drug designation, which could enhance its market exclusivity and attract future licensing partners.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.
Nuformix Plc faces severe financial challenges with no revenue generation and persistent losses, which significantly impact its stock score. While recent corporate events offer some optimism, the lack of profitability and negative valuation metrics overshadow these positives, leading to a low overall score.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix plc has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products for Orphan Drug Designation of its NXP002 programme targeting Idiopathic Pulmonary Fibrosis (IPF). This designation, pending final ratification by the European Commission, acknowledges NXP002’s potential benefit to IPF patients, particularly in combination with anti-fibrotic agents or for those intolerant to existing treatments. The designation offers developmental and commercial incentives, including 10 years of market exclusivity, enhancing Nuformix’s industry positioning and appeal to potential licensing partners.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.
Nuformix Plc faces severe financial challenges with no revenue generation and persistent losses, which significantly impact its stock score. While recent corporate events offer some optimism, the lack of profitability and negative valuation metrics overshadow these positives, leading to a low overall score.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix plc has announced a change in its registered office to a new location in London and the appointment of Shaun Zulafqar as the new Company Secretary. These changes reflect the company’s ongoing efforts to strengthen its operational framework and governance, potentially enhancing its position in the pharmaceutical development sector.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.
Nuformix Plc faces severe financial challenges with no revenue generation and persistent losses, which significantly impact its stock score. While recent corporate events offer some optimism, the lack of profitability and negative valuation metrics overshadow these positives, leading to a low overall score.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix PLC announced a correction to its earlier statement regarding the exercise of broker warrants, clarifying that the admission of new ordinary shares to the London Stock Exchange will commence on 22 April 2025, rather than the previously stated date. The issuance of 26,400,000 new shares at 0.05 pence each will raise £13,200 for the company, increasing its total voting rights to 1,695,709,368 shares, which stakeholders can use for interest calculations under FCA rules.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.
Nuformix Plc faces severe financial challenges with no revenue generation and persistent losses, which significantly impact its stock score. While recent corporate events offer some optimism, the lack of profitability and negative valuation metrics overshadow these positives, leading to a low overall score.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix plc has announced the exercise of broker warrants, resulting in the issuance of 26,400,000 new ordinary shares at a price of 0.05 pence per share, raising £13,200 for the company. These shares are set to be admitted to the Official List of the FCA and traded on the London Stock Exchange, increasing the company’s total voting rights to 1,695,709,368, which shareholders can use for interest notifications under FCA rules.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.
Nuformix Plc faces severe financial challenges with no revenue generation and persistent losses, which significantly impact its stock score. While recent corporate events offer some optimism, the lack of profitability and negative valuation metrics overshadow these positives, leading to a low overall score.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix plc has announced positive results from the re-analysis of data from previous studies of NXP002 in a precision-cut lung slice disease model. The study involved lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and autoimmune-related interstitial lung disease (ILD). The results demonstrated a clear dose response and significant effects of NXP002, suggesting its activity in additional pathways beyond current standards of care. The findings indicate that NXP002 could play a role in extracellular matrix homeostasis and support healthy tissue repair, offering potential advantages in therapeutic optionality and future product positioning. The company is in discussions with potential partners to explore these opportunities.
Spark’s Take on GB:NFX Stock
According to Spark, TipRanks’ AI Analyst, GB:NFX is a Underperform.
Nuformix Plc’s overall stock score reflects significant financial challenges, including lack of revenue and persistent losses. While the absence of debt and strong shareholder support are positives, these are overshadowed by negative cash flows and valuation concerns. Positive developments in their product pipeline and strategic initiatives provide some optimism, but financial stability remains a key hurdle.
To see Spark’s full report on GB:NFX stock, click here.
Nuformix plc announced that all resolutions proposed at its Annual General Meeting were passed, indicating strong shareholder support for the company’s current strategies and leadership. This outcome reinforces the company’s operational stability and strategic direction in the pharmaceutical industry, potentially enhancing its market position and stakeholder confidence.
Nuformix PLC has announced an update on its total voting rights following the issuance of new ordinary shares. The company’s issued share capital now consists of 1,669,309,368 ordinary shares, each with one voting right, with no shares held in treasury. This update is in accordance with the FCA’s Disclosure Guidance and Transparency Rules, providing shareholders with the necessary information to determine their interests in the company. This announcement reflects Nuformix’s compliance with regulatory requirements and may influence shareholder decisions regarding their stakes in the company.
Nuformix plc, a company specializing in drug repurposing for fibrosis and oncology, announced the posting of its Annual Financial Report for the year ending September 2024, along with the notice for its 2025 Annual General Meeting. The AGM is scheduled for March 20, 2025, and this release underscores Nuformix’s ongoing commitment to transparency and stakeholder engagement as it continues to explore early licensing opportunities in its preclinical asset pipeline.